Yiu ZZN, et al. - Using data from BADBIR, researchers conducted a prospective cohort study to compare the risk of serious infections related to infliximab use in patients with chronic plaque psoriasis vs patients on non-biologic systemic therapies. For this investigation, they compared these therapies, inclusive of any exposure to methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A or hydroxycarbamide. In patients with psoriasis in the UK and the Republic of Ireland, infliximab was correlated with an increased risk of serious infections vs non-biologic systemic therapies.